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Summary CD59 (protectin) and CD46 (membrane cofactor protein, MCP) are membrane-bound comple-
ment regulator proteins which inhibit complement-mediated cytolysis of autologous cells. CD59, a
phosphatidyl-inositol-anchored glycoprotein, inhibits the formation of the terminal membrane attack complex
(MAC) of complement and was found to be a second ligand for CD2 contributing to T-cell activation. In 20
colorectal normal mucosa samples, in ten adenomas, 71 carcinomas and in ten liver metastases derived thereof,
CD59 was inconsistently expressed in the epithelial compartment. In carcinomas CD59 expression in the whole
neoplastic compartment was more often found in well- and moderately differentiated tumours. By contrast,
focal expression or even complete lack of CD59 was more often found in poorly differentiated tumours
(P = 0.021). In addition, carcinomas without metastases at the time of operation (Dukes A/B) more often
expressed CD59 in the entire neoplastic population compared to those carcinomas which had already
metastasised (P = 0.018). There was no correlation between the mode of CD59 expression in colorectal
carcinomas and the tumour type or location. CD46 has C3b/C4b binding and factor-I dependent cofactor
activity and is broadly expressed in various cells and tissues. In the epithelial compartment of normal
colorectal mucosa, of all adenomas, carcinomas and their liver metastases, CD46 was expressed throughout
the epithelial compartment.
Since CD46 was consistently expressed in colorectal carcinomas the low expression or even lack of CD59 in
a subset of tumours might not lead to critical complement-mediated attack of CD59-negative tumour cells.
Regarding CD59 as a natural T-cell ligand involved in cognate T-cell - target-cell interaction, however, loss of
CD59 might well be a selection advantage, provided that tumour antigen-mediated T-cell toxicity in colorectal
carcinoma exists.
Membrane-bound regulatory proteins protect autologous
cells from complement mediated cytotoxicity when fragments
of the complement cascade are deposited on host cells which
are not the desired target (Davitz, 1986). These proteins
regulate the coordinating points in the classic and alternative
pathways, the formation of the C3 convertases and the
assembly of the terminal membrane attack complex (MAC)
(Kinoshita, 1991). One of these proteins which aids in
regulating the latter is protectin or CD59 (Hadam, 1989a), an
18-20 kD phosphatidyl-inositol anchored glycoprotein (Meri
et al., 1990; Ratnoff et al., 1992). CD59 restricts homologous
lysis by binding to the C8 and C9 molecules during the MAC
formation, thus disturbing the C8:C9 ratio in the MAC
complex (Meri et al., 1990; Lachmann, 1991). CD59 is
broadly expressed in human tissues, in human blood cells
and neoplastic haematopoietic cell lines (Davies et al., 1989),
vascular endothelia (Brooismans et al., 1992), various ductal
epithelia, in kidney, lung, skin and placenta (Lachmann,
1991; Meri et al., 1991; Rooney et al., 1991), in thyroid
follicular cells (Tandon et al., 1992), and spermatozoa
(Rooney et al., 1992). However, CD59 might be involved in
other immune regulatory mechanisms, such as signal trans-
duction in cells (Stefanova et al., 1991) and T-cell activation
and adhesion (Deckert et al., 1992; Venneker & Asghar,
1992) where it functions as a second ligand for CD2 (Hahn et
al., 1992). One protein which helps regulate the formation of
the C3 convertases on autologous cells (Kinoshita, 1991) and
the C5 convertase of the alternative complement pathway
(Seya et al., 1991) is the 45-70 kD membrane cofactor pro-
tein (MCP) (Lublin & Atkinson, 1989) or CD46 (Hadam,
1989b). This is a glycoprotein which acts on C3b and C4b
and, as a cofactor, induces their factor I-mediated degrada-
tion (Seya et al., 1986; Liszewsky et al., 1991). MCP is also
broadly expressed, in human fibroblasts, epithelial, and endo-
thelial cells (McNearney et al., 1989), on human oocytes and
the preimplantation blastocyst (Roberts et al., 1992), on
peripheral blood cells (Seya et al., 1990a; Cho et al., 1991), in
neoplastic haematopoietic cell lines (Caudwell et al., 1990;
Seya et al., 1990a; Cho et al., 1991), and malignant epithelial
cell lines.
Although membrane-bound complement regulatory pro-
teins have been extensively investigated on haematopoietic
and non-haematopoietic cell lines, in situ studies, especially of
solid tissues and their tumours, are still sparse. Here we
present data on the expression of CD59 and CD46 in the
normal colonic mucosa, in colorectal adenomas and car-
cinomas, and in liver metastases derived there from. To
assess a possible prognostic potential the data were cor-
related with a set of well-established tumour parameters.
Materials and methods
Immunohisto- and immunocytochemistry
Tissues and cells Tissue samples from patients who under-
went tumour resection of the colon or rectum reached our
laboratory within I h after removal. These samples were
obtained from cancers, from unaffected mucosa and from
adenomas found in the removed specimens. They were quick-
frozen in liquid nitrogen and stored at - 70°C until section-
ing. Serial sections of 4 to 6 ltm thickness were cut,
thoroughly air dried, fixed in acetone for 10min at room
temperature, then stained immediately or stored at - 20°C
for a short time. The collection comprised 20 tissue samples
of unaffected mucosa, ten adenomas, 71 carcinomas and ten
associated liver metastases. The tumours, whose primary site
and metastatic spread at the time of operation were well
documented, were typed, graded, and staged according to the
International Union Against Cancer (UICC) classification
(modified staging of the Dukes'-scheme (Dukes & Bussey,
1958) according to Turnbull et al. (Remmele, 1983); Her-
manek & Sobin, 1987; Jass & Sobin, 1989). There were six
carcinomas classified as grade I, 46 grade II, and 19 as grade
III; 57 were non-mucinous and 14 were mucinous adenocar-
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cinomas. According to the modified Dukes' staging there
were 15 stage-A patients, 26 stage-B pateints, 20 stage-C
patients and ten stage-D patients. Seventeen carcinomas were
located at the right side of the colon and 54 at the left side.
The colon carcinoma cell lines HT29 and SW480 (ATCC,
Rockville, Maryland, USA) were raised in RPMI 1640
medium (Gibco, Paisley, Scotland, UK) which contained
10% foetal calf serum, sodium pyruvate and L-glutamine.
The cells were detached with 0.25% ethylene-diamine-
tetraacetate (EDTA), centrifuged at 1,000 r.p.m. for 5 min,
and washed in RPMI 1640. Cytospin preparations were
made, air-dried, fixed in acetone for 10 min, and stained
immediately or stored at - 20°C.
Reagents andstainingprocedure CD59 (MEM-43( Stefanova
et al., 1989; IgG2a isotype; Serva, Heidelberg, Germany) and
CD46 (J4-48) (Pesando et al., 1987; IgGI isotype; Dianova-
Immunotech, Hamburg, Germany) were used for immunohis-
tochemical detection of CD59 and CD46 antigen, respectively
(Hadam, 1989a,b). Monoclonal antibody binding was de-
tected with a polyclonal biotinylated sheep antibody to
mouse immunoglobulin (Amersham, High Wycombe, UK)
and a streptavidin-biotinylated peroxidase complex (Amer-
sham). 3-Amino-9-ethylcarbazole (AEC) and N'N'-dimethyl-
formamide (DMF) were obtained from Sigma Chemical Co.
(St. Louis, Missouri, USA). Original preparations of CD59
and CD46 monoclonal antibody were diluted in the ratios
1:2,000 and 1:50 in PBS, respectively; the original prepara-
tion of biotinylated sheep antiserum to mouse immuno-
globulin was diluted 1:50 in PBS, and the streptavidin
peroxidase complex was diluted 1:100. Incubation times were
1 h at room temperature for the primary antibodies and
30 min for the second and third step reagents. Using AEC as
the chromogen (0.4 mg ml-' in 0.01% H202 for 30min), the
peroxidase reaction caused a bright red precipitate. The sec-
tions were rinsed in tapwater, counterstained in Harris'
hematoxylin and mounted with glycerol gelatin. Isotype-
matched controls with irrelevant mAb, carried out on a
limited number of normal mucosae and colon carcinomas,
revealed no isotype-associated side reactions in or on
epithelial cells. Each frozen section series contained a
negative control without the primary reagent. In this, stain-
ing was observed solely in granulocytes whose endogeneous
peroxidase was not blocked to achieve optimal antigenicity;
though to a much lesser extent, staining was also observed in
some epithelial areas, where it was assumed to be due to
endogeneous biotin.
Evaluation A semiquantitative evaluation system was used
to determine the antigen expression in normal, adenoma, and
carcinoma tissue and cells by two of us (K.K. and P.M.).
Antigen expression was scored '+' whenever specific staining
was detectable, and '-' when no antigen was detectable. To
give an indication of the relative numbers of stained and
unstained cells, sections were scored '+ > -' when stained
cells clearly outnumbered the unstained cells; '+/-' when
positive and negative cells were found in equal proportions:
'-> +' when unstained cells outnumbered the stained cells.
Using this sytem, the antigen expression was correlated with
the tumour grade, type, Dukes' stage and location of the
tumour along the large bowel. For statistical analysis Fisher's
exact test was used. The intensity of antigen expression was
verbally described, if necessary. Stromal structures that were
broadly positive for both CD59 and CD46, were used as
internal standard to evaluate normal and neoplastically
transformed epithelium.
Flow cytometry
For flow cytometry 1 x 106cells of HT29 and SW480 were
used per sample. Cells were suspended in RPMI 1640 supple- mented with 2% FCS, 10 mm HEPES and 0.1% NaN3, referred to as FACS-medium. CD21 (OKB7) was used as
isotype control for CD59 (IgG2a), CD21(BU-36) was used
as isotype control for CD46 (IgGl) (Behm et al., 1989). The
cells were incubated with the CD59 and CD46 antibodies,
diluted 1:200 and 1:10, respectively, and, after three washing
steps, with a polyclonal FITC-coupled F(ab')2 goat-anti-
mouse IgG + IgM (Dianova-Immunotech, Hamburg,
Germany), diluted 1:50. The incubation time for each
antibody was 1 h. After three washing steps propidium iodide
(1 g ml-' diluted in FACS-medium) was used to exclude
nonviable cells. Flow cytometry was performed on a FACS-
can (Becton Dickinson, Mountain View, California, USA)
with the LYSIS II software programme.
Results
Immunohistochemistry
CD59 In normal colorectal mucosa CD59 was inconsis-
tently expressed in the epithelium. 7/20 cases expressed
CD59, predominantly on the adluminal cell surface of the
upper part of the crypts. In some cases the antigen intensity
was weak. Some cases showed low amounts of CD59 antigen
in the cytoplasm and at the lateral cell borders (Figure 1).
3/20 mucosae expressed CD59 only in about half of the
epithelial compartments; 10 samples entirely lacked CD59
(Table I). Despite this heterogeneous expression of CD59 in
the epithelium, CD59 was broadly expressed in the sessile
and mobile cells of the gut wall. The endothelial cells of
small and large blood vessels strongly expressed CD59, as did
the nerve fibre bundles of the autonomic plexus. Further-
more, fibrillar structures and fibroblasts in the interstitium
were CD59 positive. The smooth muscle of the gut wall and
in the arterial vessels expressed CD59 barely at all.
Mononuclear cells of the mucosa and lymphoid cells in
lymph follicles and in outer layers of the gut wall strongly
expressed CD59.
Seven out of ten colorectal adenomas showed CD59 ex-
pression which was concentrated on the apical cell surface of
the adenoma cells (Figure 2). One adenoma lacked CD59 in
about half of the epithelial cells and two others lacked CD59
entirely (Table I).
In colorectal carcinomas CD59 expression was also
heterogeneous. 42/71 cases showed CD59 antigen in all
tumour cells, concentrated again on the apical cell border.
7/71 had more positive than negative neoplastic cells, 6/71
showed CD59 positive and negative tumour cells in about
equal parts; 5/71 tumours were predominantly negative and
11/71 entirely lacked CD59 in their epithelial compartment
(Figure 3). Stromal cells showed the same staining pattern as
the normal gut wall. In addition, fibrillar structures and
fibroblasts of the tumour stroma strongly expressed CD59.
Figure 1 Expression of CD59 in normal colon mucosa. Promi-
nent expression of CD59 in the upper part of the crypts. The
CD59 antigen is concentrated at the luminal cell surface. Stromal
cells of the mucosa express a high level of CD59 scale
bar= 77gLm.928 K. KORETZ et al.
Table I Expression of CD59 and CD46 in the epithelial compartment of normal
colorectal mucosa, adenomas and carcinomas
Normal mucosa Adenomas Carcinomas
n =20 n = 10 n = 71
Score CD59 CD46 CD59 CD46 CD59 CD46
+ 7 20 7 10 42 (59.2%) 71
+> - 0 0 0 0 7(9.8%) 0
+/- 3 0 1 0 6(8.5%) 0
->+ 0 0 0 0 5(7.0%) 0
- 10 0 2 0 11 (15.5%) 0
Notes: '+', weak or strong staining of CD59 and CD46 in all epithelial cells.
'+ > -', more positive than negative cells. '+/-', positive and negative cells in
about equal numbers. '- > +', more negative than positive cells. '-', no staining of
CD59 and CD46.
Figure 2 CD59 in a colon adenoma. Antigen density peaks at
the luminal cell surface scale bar = 77 gsm.
Figure 3 Lack of CD59 in a colon carcinoma. The tumour
nodules are completely negative, the few dark stained cells in the
tumour nodules are lymphoid cells (some marked by arrows).
The tumour stroma is strongly CD59-positive scale bar = 77 jtm.
From 41 carcinomas of the Dukes A and B group, 29
expressed CD59 in the whole tumour and 12 showed a focal
expression or a complete loss of CD59. In contrast, from 30
carcinomas of the Dukes C and D group, only 13 carcinomas
expressed CD59 in the whole tumour compartment, whereas
17 carcinomas showed a focal expression or a complete loss.
Tumours expressing CD59 in the whole epithelium were
found more often in the Dukes A/B group than in Dukes
C/D (P = 0.018), i.e. CD59 was more often expressed in
tumours without lymph node or liver metastases than in
tumours that had metastasised at the time of operation.
Figure 4 The liver metastasis of a colon carcinoma is CD59-
positive. The tumour border is marked by arrow heads.
Sinusoidal cells are positive (arrow); hepatocytes are CD59-
negative scale bar = 77tLm.
From 52 grade I and II carcinomas 35 expressed CD59 in the
whole tumour and 17 showed a focal expression or a com-
plete loss. In contrast, from 19 grade III carcinomas only
seven expressed CD59 in the whole tumour and 12 showed a
focal expression or a complete loss. Well- and moderately
differentiated tumours more often expressed CD59 in the
whole epithelial compartment compared to less differentiated
tumours (P = 0.021).
There was no significant correlation between the mode of
CD59 expression and the tumour type or location.
In the ten liver metastases CD59 expression mainly corre-
sponded to that found in their primaries. In 6/10 metastases
a similar expression of CD59 was found when compared with
their primary tumours, in 1/10 a lower antigen expression
was found, and in 3/10 a higher expression of CD59 was
found in the metastases. Peritumorous hepatocytes of the
liver metastases were CD59-negtive. The bile ducts and bile
ductuli were strongly CD59-positive, as were the sinusoids
and the endothelial cells of larger blood vessels (Figure 4).
CD46 In normal colorectal mucosa CD46 was expressed
throughout the epithelium with no microtopographic
differences along the crypts. Although the cell membranes
were prominently stained, the cytoplasmic compartment was
strongly positive, too (Figure 5). CD46 was also broadly
expressed in the sessile and mobile cells of the gut wall:
CD46 antigen density was high in endothelial cells of small
and large blood vessels, intermediate in smooth muscle cells
of the gut wall and the blood vessels, as well as in the nerve
fibre bundles of the gut plexus, and low in a subset of
fibroblasts and fibrillar structures. Most of the mononuclear
cells within the lamina propria were CD46-positive. Lym-
phocytic cells and dendritic cells of lymph follicles strongly
expressed CD46.CD59 AND CD46 IN COLORECTAL CARCINOMAS 929
Figure 5 Expression of CD46 in normal colon mucosa. Colon
epithelium and stromal cells are strongly CD46-positive scale
bar = 77jm.
Figure 7 CD46 in a moderately differentiated non-mucinous
colon adenocarcinoma. Neoplastic epithelium is strongly CD46-
positive whereas the peritumoral stroma is only slightly positive
scale bar = 77gm.
Figure 6 CD46 in a colon adenoma. The antigen is confined to Figure 8 CD46 expression in colon carcinoma cells of a liver
the cell membrane and, in lower antigen density, to the cytoplasm metastasis. The antigen is predominantly located at the cell sur-
of the tumour cells scale bar = 77lim. face scale bar = 77 tLm.
In colorectal adenomas CD46 was found in the epithelium
of all ten tumours with a staining pattern and antigen inten-
sity corresponding to the CD46 expression in normal mucosa
(Figure 6).
CD46 was consistently expressed in all colorectal car-
cinomas (Figure 7, Table I). The CD46 antigen density was
often found to be higher in the neoplastic than in the adja-
cent non-neoplastic epithelium. The tumour stroma, i.e.
fibroblasts and fibrillar structures, were slightly CD46-
positive.
The cells of the liver metastases examined were likewise
strongly CD46-positive (Figure 8). CD46 expression was at a
high level in the biliary ductuli and ducts and in the
sinusoidal system of the surrounding liver parenchyma, the
hepatocytes were slightly CD46-positive.
Immunocytochemistry andFACScan®' analysis
Cytospin preparations from SW480 and HT29 showed a
strong expression of CD59 (Figure 9) and CD46 (Figure 10)
in the cytoplasm. The maximum antigen density, however,
was confined to the cell membrane. The FACScan® analysis
demonstrated that under cell culture conditions both comple-
ment regulatory proteins were strongly surface-expressed on
both colon carcinoma lines (Figure 11).
Discussion
Recently, we have reported that the decay-accelerating factor
(DAF, CD55) is only sporadically expressed in colorectal
Figure 9 Cytospin preparation of the colon carcinoma cell line
SW480 showing CD59 in the cytoplasm and on the cell mem-
brane (x 130).
epithelium, but is up-regulated in considerable percentages of
colon adenomas and carcinomas. Expression was especially
high in carcinomas of the mucinous type (Koretz et al.,
1992), which itself has a poorer prognosis than non-mucinous
colorectal carcinomas. The present study adds further insight
in the expression of complement regulatory membrane pro-
teins in normal and neoplastic colorectal epithelium. CD59930 K. KORETZ et al.
Figure 10 Cytospin preparation of the colon carcinoma cell line
HT29 showing cytoplasmic and surface staining for CD46
(x 130).
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Figure 11 Flow-cytometric analysis of the cell surface expression
of CD46 and CD59 in the colon carcinoma cell line SW480 and
HT29. CD21 (BU-36) was used as isotype control for CD46,
CD21 (OKB7) was used as isotype control for CD59.
expression was found to be heterogeneous in both normal
and neoplastic conditions. In normal colorectal epithelium,
presence vs absence of CD59 was not associated with any
obvious microtopographical condition. In colorectal car-
cinomas the expression of CD59 was correlated with their
grade of differentiation and the stage of the disease, i.e.,
carcinomas exhibiting a low grade of differentiation and
carcinomas which had already metastasized at the time of
operation significantly more often lacked CD59 in the neo-
plastic compartment.
The biological effects of complement regulatory proteins
CD55 and CD59 on colon epithelium are unknown. It has
been suggested that presence of CD55 and presence or up-
regulation of CD59 are crucial in preventing a potential cell
lysis by autologous complement (Davitz, 1986; Tandon et al.,
1992). We have shown here that CD46 is consistently ex-
pressed in normal and neoplastic colorectal epithelium. Thus,
the physiological regulation of CD46 expression is unaffected
by neoplastic transformation in this cell type. Since CD46
alone sufficiently inhibits the complement cascade at an early
stage in some cell lines (Seya et al., 1990b), the appearance of
complement-inhibitors that act during later steps might be
redundant. As the biological functions of cell-surface comple-
ment regulator proteins on colon epithelium are unknown at
present, their possible involvement in tumour surveillance
will have to be investigated in in vitro studies.
Apart from their complement regulatory role, CD55 and
CD59 have recently been shown to exhibit additional
immune functions. CD55 expression on target cells had an
inhibitory effect on cytotoxicity by natural killer cells
(Finberg et al., 1992). CD59 was demonstrated to adhere to
and activate T-cells (Deckert et al., 1992) through its capacity
to interact with CD2 (Hahn et al., 1992). The binding site on
CD2 for CD59 was found overlapping but nonidentical with
the binding site of the well-known counter receptor which is
the lymphocyte function-associated antigen-3 (LFA-3; CD58)
(Hahn et al., 1992). In vitro, both CD58 and CD59 antibody
alone were shown to reduce the CD2-dependent response of
a murine T-cell clone expressing human CD2 (Hahn et al.,
1992). It is thus conceivable that presence of CD59 on the
cell surface might compensate a reduction or loss of LFA-3
(CD58) which has been reported to occur in some colorectal
carcinomas (Smith et al., 1989; Koretz et al., 1991). In view
of the novel functions attributed to CD55 and CD59,
presence of CD55 and absence of CD59 might contribute to
resistance of a tumour cell to cell-mediated cytotoxicity unre-
stricted and restricted, respectively, by the major histocom-
patibility complex (Browning & Bodmer, 1992; Moller &
Hammerling, 1992).
CD59 and CD46 are cell surface molecules known to act
as complement regulator proteins. The functional properties
of CD59 suggest it belongs to the group of cell surface
molecules that are involved in T-cell - target-cell interaction
and CD59 might therefore play a role in MHC-restricted
cytotoxicity. The role of CD59 in colorectal carcinoma re-
mains to be elucidated in functional studies.
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